XML 43 R23.htm IDEA: XBRL DOCUMENT

Collaborative Agreements	12 Months Ended
Collaborative Agreements	Dec. 31, 2021
Collaborative Agreements
Collaborative Agreements	Collaborative Agreements University of Pennsylvania In October 2018, as amended, the Company entered into a collaboration agreement with the University of Pennsylvania ("Penn") to pursue research and development of novel gene therapies. The Company's gene therapy portfolio pipeline expanded to include Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), ceroid lipofuscinosis, neuronal ("CLN1"), Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). This expanded collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of other rare diseases. Under the expanded collaboration agreement with Penn, Penn is eligible to receive certain milestone, royalty and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of $88.0 million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country- by-country basis. The Company will provide $10.0 million each year during the five-year agreement to fund the discovery research program. GlaxoSmithKline In July 2012, as amended in November 2013, the Company entered into an agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus obtained global rights to develop and commercialize Galafold® as a monotherapy and in combination with ERT for Fabry disease (“Collaboration Agreement”). Under the terms of the Collaboration Agreement, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. The contingent milestone payments due to GSK are recorded within the short term and long term deferred reimbursements accounts on the Consolidated Balance Sheets. Sales based tiered royalties due to GSK are recorded within the cost of goods sold within the Consolidated Statements of Operations. For the year ended December 31, 2021, under the GSK collaboration agreements, the Company paid $1.5 million in sales-based milestones and the Company incurred approximately $25.4 million of royalty expenses. As of December 31, 2021, $7.4 million was recorded as deferred reimbursements and the Company recognized a liability of $4.5 million related to royalties payable to GSK in accounts payable and accrued expenses in the Consolidated Balance Sheets.